argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
723.30
-1.50 (-0.21%)
At close: Feb 20, 2026
Market Cap38.61B +22.1%
Revenue (ttm)2.74B +93.0%
Net Income1.14B
EPS17.31
Shares Outn/a
PE Ratio33.85
Forward PE26.33
Dividendn/a
Ex-Dividend Daten/a
Volume3,627
Average Volume44,769
Open702.90
Previous Close724.80
Day's Range707.00 - 724.40
52-Week Range456.80 - 809.80
Beta-0.17
RSI57.20
Earnings DateFeb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements